The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer

Circulating angiogenic factors are altered in patients with mCRC receiving bevacizumab. Evaluation of alterations in levels of VEGF ligands may provide insights into possible resistance mechanisms. PlGF, VEGF-A, VEGF-C, and VEGF-D were measured from two cohorts of patients. Sequential plasma samples...

Full description

Bibliographic Details

Published in:	PloS one 2013-10, Vol.8 (10), p.e77117-e77117
Main Authors:	Lieu, Christopher H, Tran, Hai, Jiang, Zhi-Qin, Mao, Muling, Overman, Michael J, Lin, E, Eng, Cathy, Morris, Jeffrey, Ellis, Lee, Heymach, John V, Kopetz, Scott
Format:	Article
Language:	eng
Subjects:	Angiogenesis Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use Bevacizumab Biomarkers Biopsy Breast cancer Cancer Cancer metastasis Cancer therapies Care and treatment Causation Chemotherapy Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - blood Colorectal Neoplasms - drug therapy Colorectal Neoplasms - metabolism Colorectal Neoplasms - pathology Cytokines Development and progression Disease Progression Disease-Free Survival Drug Resistance, Neoplasm Female Health aspects Humans Ligands Male Membrane Proteins - blood Membrane Proteins - metabolism Metastases Metastasis Middle Aged Molecular Targeted Therapy Monoclonal antibodies Neoplasm Metastasis Oncology Patients Plasma Radioactive half-life Targeted cancer therapy Vascular endothelial growth factor Vascular Endothelial Growth Factor A - blood Vascular Endothelial Growth Factor A - metabolism
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!